A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998.

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

For those who may need relief from pain, Journavx symbolizes not only a new option but also a significant step forward in how we can tackle the challenges of pain management in the 21st century. The ...

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

Introducing Journavx as a Safe Opioid Alternative for Pain Relief"** In a notable development, the FDA has granted approval for Journavx, positioning it as a viable alternative to opioids for pain ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...